ANI Pharmaceuticals prices upsized $275M 2.25% convertible notes due 2029

ANI PHARMACEUTICALS INC

Aggregate principal $275M (upsized from $250M); net proceeds ~$266.8M (or ~$306.8M if full option exercised).
Notes bear 2.25% interest semi-annually, mature Sept 1, 2029; initial conversion price ~$74.11/share, 30% premium.
Proceeds: ~$35.3M for capped call transactions; remainder to repay existing senior secured term loan facility.
Company plans new $325M delayed draw term loan and $75M revolving facility concurrently with closing.
Initial purchasers have 13-day option to purchase additional $41.25M principal amount of notes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.